Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) tumbled 21% following the release of positive clinical trial results for their DURAVYU™ treatment, confounding analysts who viewed the ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Leaders of the Common Sense Oncology initiative, launched 1.5 years ago as “a new patient-centered movement in cancer care,” outline principles for trial design, analysis, and reporting.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the completion of enrollment in the explore-CKD phase 2 trial for ...

LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...